|Bid||57.35 x 1100|
|Ask||58.00 x 1100|
|Day's Range||56.25 - 59.88|
|52 Week Range||36.15 - 151.80|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.30|
Any way you look at it, Moderna (NASDAQ: MRNA) is on a roll. Here's why Moderna just booked another $3 billion in vaccine orders and no one seemed to care. Moderna announced last week that the U.S. government was buying another 200 million doses of its COVID-19 vaccine.
BERLIN (Reuters) -German financial watchdog BaFin is investigating possible insider trading of vaccine maker's CureVac shares, which fell after the biotech firm announced its COVID-19 vaccine proved only 47% effective, Rheinische Post newspaper reported on Monday. BaFin will investigate whether employees at CureVac or Bayer could have used their insider knowledge of the vaccine study results and sold shares in good time, the newspaper added. Shares in CureVac dropped more than 50% on Thursday following the company's announcement, erasing more than 6 billion euros ($7.2 billion) from the company's market value.
On June 17, shares of CureVac (NASDAQ: CVAC) plunged by over 50% during the trading session after the company announced its mRNA coronavirus vaccine candidate CVnCoV had achieved just 47% overall efficacy in preventing COVID-19 during the second interim analysis of a pivotal phase 3 study. Suspicions about the vaccine candidate's potential had already been spreading after it passed the first interim analysis without disclosure of efficacy rates. Just what are the odds that CureVac stock can recoup its losses?